ARS Corp (SPRY): Rasio rega marang prakiraan pendapatan
The forward price-to-sales ratio for ARS Pharmaceuticals (SPRY) reflects market expectations, with the value 3.10 representing the current figure. This trend is driven by nasal adrenaline patents and strict FDA oversight. Business flexibility is maintained by outsourcing production and testing to third-party contractors. A sophisticated supplier redundancy system ensures supply stability, minimizing logistical risks.
Rincian metrik keuangan lan pasar ARS Corp (SPRY)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- informasi babagan utang lan solvabilitas:
Utang marang Ekuitas ARS Pharmaceuticals|SPRY - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang modal ARS Pharmaceuticals|SPRY - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku ARS Corp|SPRY - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan ARS Pharmaceuticals|Likuiditas cepet ars-pharma.com
- data bathi bisnis lan rasio investasi:
SPRY - Penghasilan resik|Proyeksi bathi mangsa ngarep ARS Pharmaceuticals|SPRY - Pangali P/E|Pangali Forward P/E ARS Pharma|SPRY - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA ARS Corp|SPRY - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan ARS Pharmaceuticals|SPRY - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan ars-pharma.com|SPRY - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep ARS Pharmaceuticals
- indikator volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:ARS Pharmaceuticals, Inc. SPRY
The forward P/S ratio assesses the market value of an asset relative to expected revenues, filtering out speculative noise. By analyzing the projected P/S multiple on GURU.Markets, an investor compares the market capitalization of ARS Pharmaceuticals (SPRY) with the sales potential of its innovative epinephrine nasal spray. This trend reflects market expectations regarding the commercialization of needle-free medications. The stability of this metric confirms the fundamental resilience of the business within the emergency medicine sector.
Pesaing ARS Pharmaceuticals
Multiplikator Forward P/S HLN (Haleon)|Multiplikator Forward P/S Kenvue Inc KVUE|VRNA - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan MENS (Jyong Bio)|Ligand Pharmaceuticals (LGND) - Rasio rega marang prakiraan pendapatan|AMRX - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PRGO|ALVO: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Liquidia Technologies (LQDA)|GLPG: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals)|Rega forward marang dodolan MNKD|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|PCRX - Multiplikator Forward P/S|Theravance (TBPH) - Rasio rega marang prakiraan pendapatan|Aquestive Corp - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan scPharmaceuticals, Inc.|Multiplikator forward rega marang pendapatan Tectonic (TECX)|Multiplikator Forward P/S TNXP|Multiplikator Forward P/S sxtchina.com (SXTC)|Multiplikator Forward P/S EPRX (Eupraxia Pharmaceuticals Inc.)|BHST - Multiplikator forward rega marang pendapatan|eXoZymes Inc - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Oramed Pharmaceuticals|ENTX (enterabio.com) - Multiplikator forward rega marang pendapatan|MindWalk Holdings, Inc. (HYFT) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan ABVC|CPIX (Cumberland Corp) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S QNTM|Rasio kapitalisasi marang dodolan sing dikarepake fibrogen.com|Multiplikator Forward P/S TELO (Telomir Pharmaceuticals, Inc.)|RANI - Multiplikator forward rega marang pendapatan|Synergy CHC Corporation - Multiplikator Forward P/S|RLYB - Multiplikator Forward P/S|lexariabioscience.com (LEXX) - Rasio rega marang prakiraan pendapatan|PULM (pulmatrix.com) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Pheton Holdings Limited|Aptorum (APM) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Lyra Therapeutics, Inc (LYRA)|Rasio kapitalisasi marang dodolan sing dikarepake Impact BioMedical, Inc.|Rasio rega marang prakiraan pendapatan TNF Pharmaceuticals, Inc. TNFA|YCBD (cbdMD Inc.) - Rega mangsa ngarep marang pendapatan|PRFX - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan CYTO (Altamira Therapeutics)|LIPO (Lipella) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OptiNose Corp (OPTN)|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|procapsgroup.com - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S PTPI|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Multiplikator Forward P/S SLRN (ACELYRIN, Inc.)|Multiplikator Forward P/S TFF Pharmaceuticals, Inc TFFP
